Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.The company operates six manufacturing facilities with a combined production capacity of 50,000 MT, specializing in minerals such as calcium, iron, magnesium, zinc, potassium, and sodium The company supplies more than 200 products to a diverse customer base across pharma, food, and nutrition sectorsThe company has strong R&D capabilities with in-house labs and pilot-scale facilities focused on mineral salts and excipients.Product Portfolio:Pharmaceutical, Food and Nutrition BusinessSpecialty Ingredients BusinessTrituratesAs of December 31, 2024, the company had 704 permanent employees.Competitve Strengths:Market leadership with a diversified product portfolio in a high barrier industryDistinguished global customer base with long-standing relationships with key customersWell-equipped and regulatory compliant Manufacturing FacilitiesStrong research and development capabilities
| Category | Shares Offered* | Total Amt* (₹ Cr.) |
|---|---|---|
|
QIB (Ex Anchor)
|
7,546,376 | ₹447.500 |
|
NII
|
2,263,912 | ₹134.250 |
|
Retail
|
5,282,462 | ₹313.250 |
| Total ** | 15,092,750 | ₹895.000 |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min — 2 Lots) | 2 | 50 | ₹29,650 |
| Retail (Max — 13 Lots) | 13 | 325 | ₹192,725 |
| S-HNI (Min — 14 Lots) | 14 | 350 | ₹207,550 |
| S-HNI (Max — 66 Lots) | 66 | 1,650 | ₹978,450 |
| B-HNI (Min — 67 Lots) | 67 | 1,675 | ₹993,275 |
| Category | QIB | NII | Retail | Total | ||||
|---|---|---|---|---|---|---|---|---|
| Ex. Anchor | Anchor Investor | Total QIB | Below ₹10L | Above ₹10L | Total NII | |||
| Allocation (No. of shares) | — | — | — | — | — | 2,263,912 | 5,282,462 | 7,546,374 |
| Allotment price (Rs.) | 593 | 593 | 593 | 593 | 593 | 593 | 593 | 593 |
| No. of applications | — | — | — | — | — | — | — | — |
| No. of shares applied | — | — | — | — | — | — | — | — |
| Amount collected (Rs.cr.) | 447.50 | — | 447.50 | — | — | 134.25 | 313.25 | 895.00 |
| No. of times subscribed | — | — | — | — | — | — | — | — |
| No. of shares allotted | — | — | — | — | — | 2,263,912 | 5,282,462 | 7,546,374 |
| Amount (Rs.cr.) | 447.50 | — | 447.50 | — | — | 134.25 | 313.25 | 447.50 |
| No. of allottees | — | — | — | — | — | — | — | — |
| Category | Shares Offered | Amt (₹ Cr) | Size (%) |
|---|---|---|---|
| QIB (Ex Anchor) | 7,546,376 | ₹447.50 |
50.00%
|
| NII / HNI | 2,263,912 | ₹134.25 |
15.00%
|
| Retail (RII) | 5,282,462 | ₹313.25 |
35.00%
|
| Total | 15,092,750 | ₹895.00 |
100.00%
|
| Particulars | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue from Operations | 130.08 | 511.33 | 465.38 |
| EBITDA | 48.57 | 199.28 | 187.76 |
| Profit After Tax (PAT) | 31.27 | 138.69 | 133.15 |
| Net Worth | 688.32 | 497.53 | 359.07 |
| Total Assets | 922.26 | 717.17 | 513.87 |
| Reserves & Surplus | 668.52 | 481.11 | 354.59 |
| Total Borrowings | 135.97 | 135.25 | 75.03 |
| EBITDA Margin (%) | 39.70% | — | — |
| PAT Margin (%) | 27.63% | — | — |
Sudeep Pharma Ltd. proposes to utilize the net proceeds raised through this IPO for the following objects as stated in the Draft Red Herring Prospectus (DRHP) filed with SEBI: